DIAGNOSTIC TECHNIQUE FOR EARLY DISORDERS OF CARBOHYDRATE METABOLISM IN PATIENTS WITH CHRONIC PANCREATITIS Russian patent published in 2024 - IPC G01N33/68 G01N33/573 G01N1/28 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to laboratory diagnostics, gastroenterology, endocrinology, and can be used for diagnosis of early disorders of carbohydrate metabolism in patients with chronic pancreatitis. Blood is sampled from patient’s vein, blood serum is obtained, reagents are prepared for analysis, optical density of solutions is measured. Patient's venous blood is centrifuged to obtain blood serum for 20 minutes at acceleration of 1,000 g, phosphate-salt solution with concentration of 0.01 mol/l is used as a buffer solution, pH of the prepared solution should be 7.18-7.22. 15 minutes before the analysis, a solution of the Orexin A standard is prepared, as a result of which 5 points are obtained: 1000; 333.33; 111.11; 37.04; 12.35 pg/ml. Analysis is carried out with the help of reagents, at each stage of analysis, after washing, residues of washing solution are removed from the plate, humidity of ambient air is maintained less than 60 % and the solution is protected from action of sun rays. Using a microplate reader, measurements are taken at wavelength 450 nm, average values of optical density for standards, controls and samples are calculated when analysing in duplicates. Using the obtained values, a calibration curve is plotted; the logarithm of concentration of each Orexin A standard is plotted along the Y axis, and the optical density of the corresponding standard is plotted along the X axis. Orexin A concentration in the samples is determined by comparing the obtained optical density of the samples with the plotted calibration curve. If the Orexin A value is more than 99.9 pg/ml, early disorders of carbohydrate metabolism are diagnosed in the patients with chronic pancreatitis.

EFFECT: method enables detecting early disorders of carbohydrate metabolism in patients with chronic pancreatitis, which prevents the development of severe complications of pancreatic diseases, by determining the concentration of Orexin A in the patients' blood.

1 cl, 4 dwg, 5 tbl, 3 ex